SELUTION SLR PTCA Drug Eluting Balloon
The SELUTION SLR™ Drug Eluting Balloon (DEB) is the latest generation of drug-eluting balloon technology designed to Go Beyond Metal and deliver consistent and predictable drug release as best-in-class drug-eluting stents.
- The New Paradigm for Coronary Interventions
Breakthrough technology to deliver sustained limus release up to 90 days.
CELL ADHERENT TECHNOLOGY
CELL ADHERENT TECHNOLOGY (CAT)™ facilitates drug uptake and retention, in the tissue, with a minimal drug loss during the procedure while providing excellent deliverability.
MICRORESERVOIRS
MicroReservoirs achieve a consistent and predictable drug release, at a therapeutic level, comparable to the latest generation drug-eluting stent technology
SIZE MATRIX
SELUTION SLR DEB offers a broader portfolio to extend treatment options for coronary artery disease
The SELUTION DeNovo Study1
A prospective randomized, multi-center, international, single-blind clinical trial comparing the SELUTION SLR DEB Strategy Versus Drug-Eluting Stent (DES) Strategy.
- Landmark randomized trial for coronary de-novo lesions, all-comers enrollment
- Designed to evaluate non-inferiority at 1 and 5 years and possible superiority at 5 years
- Primary Endpoints: Target Vessel Failure at 1 year and 5 years
ADVANCING DRUG-ELUTING BALLOON EDUCATION
Empowering healthcare practitioners through professional education initiatives including these webinars:
- DEB in Bifurcations: Simplifying the Complex
- DCB PCI in clinical practice: negotiating the learning curve
- Minimal-metal PCI: a drug-coated balloon philosophy combined with selective lesion stenting where necessary - the hybrid approach
- From Access to Closure through Treatment: How to Maximize Outcomes while Minimizing Impact
- Go beyond metal: exploring drug-eluting balloon technology in de novo coronary lesions – EuroPCR 2024
